Zolgensma – more than just the world’s most expensive drug
The US Food and Drug Administration (FDA) recently approved Zolgensma, Novartis’ one-dose gene therapy for the treatment of paediatric patients (less than two years of age) suffering from spinal muscular atrophy (SMA), a rare but life-threatening disease. Zolgensma was acquired by Novartis as a part of the $8.7 billion acquisition of AveXis last year. Being one of the earliest gene therapies in the market, Zolgensma is unprecedented in many aspects. In our latest blog, we look at the market for this drug, including pricing considerations and its future potential.
Become a contributor